CYCLACEL PHARMACEUTICALS INC (CYCC)
US23254L6039 - Common Stock
We assign a fundamental rating of 2 out of 10 to CYCC. CYCC was compared to 602 industry peers in the Biotechnology industry. While CYCC seems to be doing ok healthwise, there are quite some concerns on its profitability. CYCC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CYCC has reported negative net income.
In the past year CYCC has reported a negative cash flow from operations.
CYCC had negative earnings in each of the past 5 years.
In the past 5 years CYCC always reported negative operating cash flow.
1.2 Ratios
CYCC's Return On Assets of -145.80% is on the low side compared to the rest of the industry. CYCC is outperformed by 87.12% of its industry peers.
The Return On Equity of CYCC (-248.91%) is worse than 75.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -145.8% | ||
| ROE | -248.91% | ||
| ROIC | N/A |
ROA(3y)-52.13%
ROA(5y)-49.33%
ROE(3y)-65.19%
ROE(5y)-62.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CYCC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYCC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYCC has been increased compared to 5 years ago.
CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CYCC has an Altman-Z score of -40.30. This is a bad value and indicates that CYCC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -40.30, CYCC is not doing good in the industry: 95.82% of the companies in the same industry are doing better.
There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -40.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CYCC has a Current Ratio of 2.27. This indicates that CYCC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.27, CYCC is not doing good in the industry: 77.09% of the companies in the same industry are doing better.
CYCC has a Quick Ratio of 2.27. This indicates that CYCC is financially healthy and has no problem in meeting its short term obligations.
CYCC has a worse Quick ratio (2.27) than 75.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
CYCC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.53%.
EPS 1Y (TTM)1.53%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q4.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 21.29% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.78%
EPS Next 2Y-38.44%
EPS Next 3Y-35.61%
EPS Next 5Y21.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CYCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYCC's earnings are expected to decrease with -35.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.44%
EPS Next 3Y-35.61%
5. Dividend
5.1 Amount
No dividends for CYCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYCLACEL PHARMACEUTICALS INC
NASDAQ:CYCC (11/28/2023, 7:00:00 PM)
0.2982
+0.01 (+3.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)03-04 2024-03-04/amc
Inst Owners9.39%
Inst Owner Change-42.48%
Ins Owners3.62%
Ins Owner Change27.85%
Market Cap3.77M
Analysts86
Price Target12.5 (4091.82%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)-48.55%
DP-0.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.42%
Min EPS beat(2)14.3%
Max EPS beat(2)30.53%
EPS beat(4)3
Avg EPS beat(4)12.46%
Min EPS beat(4)-21.91%
Max EPS beat(4)30.53%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0%
PT rev (3m)-9.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.92%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.19 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.39 | ||
| P/tB | 0.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.93
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS0.03
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -145.8% | ||
| ROE | -248.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-52.13%
ROA(5y)-49.33%
ROE(3y)-65.19%
ROE(5y)-62.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 33.33% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.27 | ||
| Altman-Z | -40.3 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)202.78%
Cap/Depr(5y)158.33%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)1.53%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q4.35%
EPS Next Y11.78%
EPS Next 2Y-38.44%
EPS Next 3Y-35.61%
EPS Next 5Y21.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-81.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.63%
OCF growth 3YN/A
OCF growth 5YN/A